---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-25-000076"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:35:09.040868+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad posts GAAP net loss of $342M in Q3 2025; non-GAAP EPS rises to $2.26

## Summary
- Revenue $653.0M, up slightly from $649.7M year-over-year.
- GAAP net loss $341.9M ($12.70 loss per diluted share) vs net income $653.2M in Q3 2024.
- Non-GAAP net income $60.8M ($2.26 per share) vs $56.3M ($2.02) in prior year.
- GAAP gross margin declined to 52.6% from 54.8%; non-GAAP gross margin declined to 53.5% from 55.6%.
- CEO cited disciplined cost management for better-than-expected operating margin despite funding headwinds.

## SEC filing metadata
- accession: 0000012208-25-000076
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220825000076/0000012208-25-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220825000076/bio-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-25-000076
- JSON: https://secwatch.observer/filing/0000012208-25-000076.json
- Plain text: https://secwatch.observer/filing/0000012208-25-000076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.